PMID- 22458574
OWN - NLM
STAT- MEDLINE
DCOM- 20120731
LR  - 20161125
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 10
IP  - 4
DP  - 2012 Apr
TI  - Bivalirudin for primary percutaneous coronary intervention in acute myocardial 
      infarction: the HORIZONS-AMI trial.
PG  - 411-22
LID - 10.1586/erc.12.24 [doi]
AB  - The combination of unfractionated heparin (UFH) plus glycoprotein IIb/IIIa 
      inhibitors (GPIs) has been a frequently used anti-thrombotic treatment strategy 
      for acute coronary syndrome patients, including those with ST-segment elevation 
      myocardial infarction undergoing primary percutaneous coronary intervention. 
      However, the ischemic benefit of the UFH plus GPI combination came at the expense 
      of high rates of bleeding complications and thrombocytopenia, both of which have 
      been independently associated with increased mortality. By contrast, bivalirudin 
      monotherapy compared with the combination of UFH plus GPI resulted in improved 
      net clinical outcomes, based on similar ischemic protection with significant 
      reductions in bleeding complications in randomized trials including patients with 
      stable angina, those with unstable angina and those with non-ST-segment elevation 
      myocardial infarction. More recently, the HORIZONS-AMI randomized, open-label, 
      multicenter trial has compared the efficacy and safety of bivalirudin alone 
      versus UFH plus a GPI in 3602 patients with ST-segment elevation myocardial 
      infarction undergoing primary percutaneous coronary intervention. Clinical 
      results derived from this large study, including the final 3-year follow-up data, 
      will be reviewed in the present clinical trial report.
FAU - Capranzano, Piera
AU  - Capranzano P
AD  - Cardiovascular Department, Ferrarotto Hospital, University of Catania, Italy.
FAU - Dangas, George
AU  - Dangas G
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
RN  - 0 (Antithrombins)
RN  - 0 (Hirudins)
RN  - 0 (Peptide Fragments)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 0 (Recombinant Proteins)
RN  - 9005-49-6 (Heparin)
RN  - TN9BEX005G (bivalirudin)
SB  - IM
MH  - *Angioplasty, Balloon, Coronary
MH  - Antithrombins/adverse effects/*therapeutic use
MH  - Combined Modality Therapy
MH  - Drug Therapy, Combination
MH  - Heparin/*therapeutic use
MH  - Hirudins/adverse effects
MH  - Humans
MH  - Myocardial Infarction/complications/mortality/*therapy
MH  - Peptide Fragments/adverse effects/*therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Recombinant Proteins/adverse effects/therapeutic use
MH  - Treatment Outcome
EDAT- 2012/03/31 06:00
MHDA- 2012/08/01 06:00
CRDT- 2012/03/31 06:00
PHST- 2012/03/31 06:00 [entrez]
PHST- 2012/03/31 06:00 [pubmed]
PHST- 2012/08/01 06:00 [medline]
AID - 10.1586/erc.12.24 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2012 Apr;10(4):411-22. doi: 10.1586/erc.12.24.